Affidea Group, Europe’s leading provider of advanced diagnostics, community-based polyclinics and specialised healthcare services including oncology, announces the acquisition of a majority stake in LabPoint S.A. from Lindenhofgruppe. LabPoint S.A. is a medical diagnostics laboratory and a recognised player in laboratory medicine, genetics, which, together with Affidea’s capability, will also have integrated pathology and cytology in Switzerland.

Founded in 2022 by Lindenhofgruppe, LabPoint has recorded remarkable growth and has successfully established a strong and sustainable position in the market. Labpoint operates across five locations in Avenches, Bern, Ticino, Vaud and Basel, as well as several blood collection points in the cantons of Bern, Fribourg, Ticino, Vaud, Zurich, Jura and Basel. These new locations complement Affidea’s existing network of 33 imaging and specialist centres across the country, bringing the total workforce to 870 employees.

This strategic transaction marks a key milestone in the development of Affidea Switzerland, which continues to pursue its ambition of offering integrated precision medicine in the patient journey, combining imaging, comprehensive laboratory analysis and advanced medical expertise within its Centres of Excellence.

With Lindenhofgruppe, Affidea Switzerland has found a strong strategic partner. Lindenhofgruppe will remain a minority shareholder in LabPoint, while retaining its role as a key medical partner. This structure enables the hospital group to continue its responsibility towards LabPoint’s employees and to contribute meaningfully to the company’s development alongside a new reference shareholder, in order to sustainably strengthen its position and role in laboratory diagnostics.